<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28847" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Selective Beta-1 Blockers</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tucker</surname>
            <given-names>William D.</given-names>
          </name>
          <aff>ETSU Quillen College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankar</surname>
            <given-names>Parvathy</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Theetha Kariyanna</surname>
            <given-names>Pramod</given-names>
          </name>
          <aff>State Un of New York - Downstate MC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>William Tucker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parvathy Sankar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pramod Theetha Kariyanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28847.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The cardio-selective beta-1-blockers include atenolol, betaxolol, bisoprolol, esmolol, acebutolol, metoprolol, and nebivolol. FDA-approved uses of beta-1-selective blockers include hypertension, chronic stable angina, heart failure, post-myocardial infarction, and decreased left ventricular function after a recent myocardial infarction. Non-FDA-approved uses include migraine prophylaxis, treatment of arrhythmias, tremor reduction, and the symptomatic treatment of anxiety disorders. Their use is associated with decreased morbidity and mortality post-myocardial infarction. Treatment with beta-1 blockers reduces the risk of stroke, coronary artery disease, and congestive heart failure. This activity outlines the indications, mechanisms of action, methods of administration, important adverse effects, contraindications, and monitoring, of selective beta-1 antagonists, so providers can direct patient therapy in treating indicated disorders as part of the interprofessional team, with a basis on the current knowledge for optimal utilization.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for using selective beta-1 antagonist agents.</p></list-item><list-item><p>Describe the mechanism of action of selective beta-1 blockers and how it differs from non-selective agents.</p></list-item><list-item><p>Outline the potential adverse events associated with selective beta-1 antagonists.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance selective beta-1-blockers where it is indicated and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28847">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28847.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The cardio-selective beta-blockers include atenolol,&#x000a0;betaxolol, bisoprolol,&#x000a0;esmolol, acebutolol, metoprolol, and nebivolol.<xref ref-type="bibr" rid="article-28847.r1">[1]</xref>&#x000a0;FDA-approved uses of beta-1-selective blockers include hypertension, chronic stable angina, heart failure, post-myocardial infarction, and decreased left ventricular function after a recent myocardial infarction. Non-FDA-approved (off-label) uses include migraine prophylaxis,&#x000a0;treatment&#x000a0;of arrhythmias, tremor reduction, and the symptomatic treatment&#x000a0;of anxiety disorders.<xref ref-type="bibr" rid="article-28847.r2">[2]</xref>&#x000a0;Their&#x000a0;use is associated with decreased morbidity and mortality for post-myocardial infarction. Treatment with beta-1 blockers&#x000a0;reduces&#x000a0;the risk of stroke, coronary artery disease, and congestive heart failure (for example, metoprolol succinate has proven mortality benefit in the treatment of heart failure, and it is the&#x000a0;extended-release formulation of metoprolol).&#x000a0;</p>
        <p>The mortality benefits for metoprolol succinate in heart failure patients are attributed to their ability to block the toxic effects of chronic adrenergic stimulation of the heart. Initiation of metoprolol succinate in a heart failure patient is followed by clinical improvement, improved ejection fraction, and increased exercise tolerance. The benefits of left ventricular function improvement may take 2 to 3 months to observe after initiating medication.<xref ref-type="bibr" rid="article-28847.r3">[3]</xref></p>
        <p>Slow calcium channel blockers and beta-blockers are medications that affect AV nodal function. The PR interval on the EKG defines the time needed for an impulse to travel through the atrium and AV nodal system to the ventricles. AV node conduction is the slowest, and PR interval variations reflect changes in AV nodal activation time. Beta-blockers have a negative dromotropic effect on the AV node by prolonging the AV nodal refractory periods, which could prolong&#x000a0;the PR interval. The prolonged PR interval rarely results in more than first-degree AV block in patients receiving maintenance therapy.&#x000a0;In a few patients, combining a calcium channel blocker and a beta-blocker may cause a second-degree AV block.<xref ref-type="bibr" rid="article-28847.r4">[4]</xref></p>
      </sec>
      <sec id="article-28847.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Beta-1 receptors are primarily found in&#x000a0;cardiac nodal tissue, cardiac&#x000a0;myocytes, other heart conduction pathway tissues,&#x000a0;and kidneys. Beta-1 blockers exert their effect by binding to the beta-1 receptor sites selectively and inhibiting the action of epinephrine and norepinephrine on these sites. Beta-1 receptors are G-protein-coupled receptors (specifically Gs alpha subunit) whose action is exerted through&#x000a0;the cyclic AMP (cAMP)&#x000a0;and cAMP-dependent protein kinase action with&#x000a0;resultant&#x000a0;calcium ion concentration increases.<xref ref-type="bibr" rid="article-28847.r5">[5]</xref><xref ref-type="bibr" rid="article-28847.r6">[6]</xref>&#x000a0;Increased intracellular calcium increase inotropy in the heart through calcium-induced exchange facilitated by the sarcoplasmic reticulum. Myosin light chains phosphorylated by PKA lead to contractility in muscle cells.<xref ref-type="bibr" rid="article-28847.r3">[3]</xref></p>
        <p>Normally, activation of the beta-1 receptor in the heart increases sinoatrial (SA) nodal, atrioventricular (AV) nodal, and ventricular muscular firing, which leads to increased heart rate and contractility. Stroke volume and cardiac output will also increase as a result. In the kidney, renin is released when smooth muscle cells in the juxtaglomerular apparatus are activated. Blood volume is eventually increased because of the downstream production of angiotensin II and aldosterone production triggered by renin.<xref ref-type="bibr" rid="article-28847.r3">[3]</xref></p>
        <p>Ordinarily, this adrenergic response results in increased inotropy,&#x000a0;chronotropy, and&#x000a0;dromotropy. The blockade of this&#x000a0;pathway with beta-1 blockers&#x000a0;results in decreased&#x000a0;contractility (inotropy), decreased heart rate (chronotropy), increased relaxation (lusitropy), and decreased cardiac conduction times (dromotropy).&#x000a0;</p>
      </sec>
      <sec id="article-28847.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cardio-selective beta-blockers can be administered either intravenously or by mouth, depending on the desired medication. The&#x000a0;acuteness and severity of the disease symptoms affect this decision.&#x000a0;Intravenous administration allows for the immediate onset of action and complete bioavailability, while oral administration with most beta-1 blockers allows for maximal absorption between 1 to 4 hours post-ingestion. Extended-release formulations are also available for oral use, allowing for less frequent dosing.&#x000a0;Esmolol&#x000a0;is a beta-1 blocker strictly administered&#x000a0;intravenously due to its short half-life of approximately 9 minutes.</p>
        <p>Doses of cardioselective beta-blockers may require adjustments&#x000a0;in patients with renal disease. For example, atenolol&#x000a0;is a hydrophilic agent primarily excreted by the&#x000a0;kidneys. The dose&#x000a0;needs to be reduced by one-half to three-quarters in patients with diminished&#x000a0;renal&#x000a0;clearance. Lipophilic beta-blockers like metoprolol do not need to be adjusted. Conversely, metoprolol is extensively metabolized by the liver. Hepatic impairment may impact the pharmacokinetics of metoprolol. There is a prolongation of the elimination half-life of metoprolol in patients with hepatic failure.<xref ref-type="bibr" rid="article-28847.r7">[7]</xref></p>
      </sec>
      <sec id="article-28847.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects of&#x000a0;cardio-selective beta-blockers include bradycardia, decreased exercise capacity, hypotension, atrioventricular nodal block,&#x000a0;and heart failure.&#x000a0;Other common adverse effects include nausea, vomiting, abdominal&#x000a0;discomfort, dizziness,&#x000a0;weakness, headache,&#x000a0;fatigue, and dry mouth and eyes. Less common adverse effects are sexual dysfunction, memory loss, and confusion.&#x000a0;An&#x000a0;additional&#x000a0;risk of beta-1 blockers is the&#x000a0;masking&#x000a0;of&#x000a0;hypoglycemia-induced tachycardia in the diabetic patient, which is a warning sign of the patient's blood glucose levels being too low.&#x000a0;Hypoglycemia, or low blood glucose, most commonly occurs in diabetic patients due to insulin&#x000a0;or other drugs. The onset of hypoglycemic symptoms can occur at different blood glucose levels but most commonly occurs when blood glucose falls below&#x000a0;70 mg/dL.<xref ref-type="bibr" rid="article-28847.r8">[8]</xref>&#x000a0;</p>
        <p>The catecholamine-triggered neurogenic hypoglycemic symptoms masked by this class of medications include tremors and palpitations. Hunger, tremor, irritability, and confusion can be hidden as well. Sweating, however, remains unmasked and might be the only consistent sign of hypoglycemia in individuals treated with &#x003b2;-blockers.<xref ref-type="bibr" rid="article-28847.r9">[9]</xref>&#x000a0;Since continuous hypoglycemia causes acute brain damage, changes in a patient's mental status should trigger fingerstick blood glucose monitoring and treatment.&#x000a0;Treatment in responsive patients consists of fast-acting sugar like glucose tablets, candy, or juice. Intravenous dextrose or intramuscular&#x000a0;glucagon is indicated for unresponsive patients.<xref ref-type="bibr" rid="article-28847.r8">[8]</xref></p>
        <p>Some medications that may result in adverse effects when paired with beta-1 blockers include nitrates, phosphodiesterase inhibitors, ACE inhibitors, calcium channel blockers, and other blood pressure-lowering or&#x000a0;anti-arrhythmic&#x000a0;medications. Adverse effects also occur in overdose. In excessive doses,&#x000a0;cardio-selective beta-blockers lose their selective binding and begin to&#x000a0;interact with beta-2 and beta-3 adrenergic&#x000a0;receptors.<xref ref-type="bibr" rid="article-28847.r2">[2]</xref></p>
      </sec>
      <sec id="article-28847.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the American College of Cardiology, beta-1 blockers should not be prescribed to patients with a recent or current history of fluid retention without concurrent diuretic use. Beta-1 blockers are contraindicated in patients with complete heart block and should be used with great caution in patients with second-degree heart block. Beta-1 blockers generally&#x000a0;are&#x000a0;contraindicated&#x000a0;in patients with moderate to severe asthma and patients with chronic&#x000a0;obstructive pulmonary disease.<xref ref-type="bibr" rid="article-28847.r10">[10]</xref>&#x000a0;</p>
        <p>Controversy&#x000a0;exists over the safety&#x000a0;of beta-1 blocker use&#x000a0;in persons with mild to moderate asthma. Studies examining the efficacy of beta-1 blocker use in patients with concurrent mild to moderate asthma showed little to no adverse outcomes compared to those who did not have underlying asthma, but they generally are not used due to the potential risks.<xref ref-type="bibr" rid="article-28847.r11">[11]</xref></p>
      </sec>
      <sec id="article-28847.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Beta-1 blockers are monitored via the patient's vital signs. Heart rate and blood pressure checks, along with regular physical examination, are sufficient for basic patient monitoring.&#x000a0;Regular blood level monitoring of beta-1-blocker levels is not indicated&#x000a0;in most circumstances.&#x000a0;If there are reasons to be concerned about reaching therapeutic levels or&#x000a0;toxicity,&#x000a0;then blood levels of specific beta-1 blockers can&#x000a0;be&#x000a0;ordered and&#x000a0;reviewed.&#x000a0;In cases that prove to be refractory to treatment for an overdose, more intensive measures can be taken, including continuous monitoring of heart rate, cardiac electrical activity, and blood pressure.</p>
      </sec>
      <sec id="article-28847.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Beta-1 blockade toxicity&#x000a0;typically presents with the triad of bradycardia, hypotension, and altered mental status. These signs are sometimes&#x000a0;accompanied by a state of hypoglycemia and hyperkalemia, though not always.&#x000a0;Clinicians and other caregivers must remember that in an overdose, beta-1 blockers can lose their selectivity; this means bronchopulmonary symptoms may be present.&#x000a0;Additionally,&#x000a0;neurologic functioning can be impaired, resulting in&#x000a0;altered mental status&#x000a0;in toxicity&#x000a0;with highly lipophilic beta-1 blockers like propranolol,&#x000a0;acebutolol, and oxprenolol. Suspected cardio-selective beta-1-blocker toxicity needs to be verified with a meticulous history, and physical examination focused on&#x000a0;identifying specific&#x000a0;medications ingested and any co-ingestions that could affect patient treatment.<xref ref-type="bibr" rid="article-28847.r12">[12]</xref></p>
        <p>Immediate monitoring of blood&#x000a0;pressure with a blood pressure cuff&#x000a0;and cardiac electrical activity with an EKG&#x000a0;is necessary.&#x000a0;Acquiring blood glucose levels, a&#x000a0;basic metabolic panel, and acetaminophen and salicylate levels help identify sequelae of beta-1-blocker overdose and toxicity, as well as identifying any medications that may have been co-ingested.&#x000a0;In severely hypotensive patients, one should consider obtaining&#x000a0;a lactate level due to the&#x000a0;possibility&#x000a0;of mesenteric ischemia. Patients being treated within 1 to 2 hours of ingestion may benefit from activated charcoal, or gastric lavage may be necessary for patients who present immediately after large ingestions or with severe adverse symptoms.</p>
        <p>Intravenous fluid administration&#x000a0;for treatment of hypotension&#x000a0;and&#x000a0;intravenous glucagon&#x000a0;to antagonize beta-1-blocker effects&#x000a0;are the&#x000a0;initial reversal agents of choice&#x000a0;for beta-1-blocker toxicity. Following the administration of glucagon and crystalloid fluids, the patient may require calcium and sodium bicarbonate which is indicated for QRS widening and magnesium sulfate for QTc prolongation.<xref ref-type="bibr" rid="article-28847.r12">[12]</xref>&#x000a0;It is important to be aware of the potential for initial treatment failure and take steps to prepare for invasive measures. More invasive measures&#x000a0;include the use of&#x000a0;hyperinsulinemia-euglycemia&#x000a0;therapy, lipid emulsion therapy,&#x000a0;vasopressors, intubation (some lipophilic beta-blockers cause CNS depression which requires immediate stabilization of airways), or intra-aortic balloon pump if hemodynamic instability is present.<xref ref-type="bibr" rid="article-28847.r13">[13]</xref></p>
        <p>Glucagon reverses the actions of beta-blockade. Its actions increase contractility, heart rate, and conduction through the atrioventricular node. It works by binding the G-protein coupled receptor (G&#x003b1;s-coupled proteins). This increases cAMP levels through adenylate cyclase, which in turn stimulates activation of protein kinase A (PKA).<xref ref-type="bibr" rid="article-28847.r14">[14]</xref>&#x000a0;Atropine is used to counteract vagally mediated bradycardia. The mechanism of action for vagally mediated bradycardia is different than the catecholamine blockade resulting in bradycardia for the patient with selective beta-blocker overdose.<xref ref-type="bibr" rid="article-28847.r12">[12]</xref>&#x000a0;Beta-blocker-induced bronchospasm may be treated with oxygen and bronchodilators like albuterol.&#x000a0;&#x000a0;</p>
        <p>Propranolol overdoses are especially life-threatening.&#x000a0;Sotalol&#x000a0;overdoses require prolonged monitoring due to the possibility of QT interval prolongation and the potential for torsades&#x000a0;de pointes. Patients suspected of overdosing with either of these cardio-selective beta-blockers should be treated more aggressively. Patient monitoring is recommended for at least 6 hours in asymptomatic, unintentional beta-1-blocker overdose cases. In cases of overdose with propranolol, monitoring is advised for at least 12 hours. In circumstances of sotalol overdose, monitoring for 24 hours is preferable due to the potential late-onset cardiac effects.<xref ref-type="bibr" rid="article-28847.r15">[15]</xref>&#x000a0;Some&#x000a0;cardio-selective beta-blockers have intrinsic agonist activity and are used in patients with an increased risk of overdose.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-28847.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>While beta-1 blockers provide numerous benefits to patients, there is always a potential for toxicity or adverse events. The interprofessional team of&#x000a0;clinicians, pharmacists, and nurses caring for a patient on these drugs should be aware of and report any signs or symptoms of toxicity, documenting this in the patient's chart and records, and sharing this information with all interprofessional team members so that everyone is operating from the same patient data set. An interprofessional team approach to monitoring for side effects will enhance patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-28847.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28847&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28847">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28847/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28847">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28847.s11">
        <title>References</title>
        <ref id="article-28847.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ladage</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwinger</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Brixius</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-83</page-range>
            <pub-id pub-id-type="pmid">22279967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Beta Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30422501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Alhayek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Beta 1 Receptors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">30422499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prystowsky</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-21</page-range>
            <pub-id pub-id-type="pmid">2450898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kobilka</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>The structure and function of G-protein-coupled receptors.</article-title>
            <source>Nature</source>
            <year>2009</year>
            <month>May</month>
            <day>21</day>
            <volume>459</volume>
            <issue>7245</issue>
            <fpage>356</fpage>
            <page-range>356-63</page-range>
            <pub-id pub-id-type="pmid">19458711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Serrano-Vega</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Moukhametzianov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Schertler</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Structure of a beta1-adrenergic G-protein-coupled receptor.</article-title>
            <source>Nature</source>
            <year>2008</year>
            <month>Jul</month>
            <day>24</day>
            <volume>454</volume>
            <issue>7203</issue>
            <fpage>486</fpage>
            <page-range>486-91</page-range>
            <pub-id pub-id-type="pmid">18594507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <chapter-title>Beta Adrenergic Blocking Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mathew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thoppil</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Hypoglycemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">30521262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Dangerous and common drug interactions in patients with diabetes mellitus.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-802</page-range>
            <pub-id pub-id-type="pmid">11149162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salpeter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ormiston</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Salpeter</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2002</year>
            <month>Nov</month>
            <day>05</day>
            <volume>137</volume>
            <issue>9</issue>
            <fpage>715</fpage>
            <page-range>715-25</page-range>
            <pub-id pub-id-type="pmid">12416945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[True and presumed contraindications of beta blockers. Peripheral vascular disease, diabetes mellitus, chronic bronchopneumopathy].</article-title>
            <source>Ital Heart J Suppl</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>8</issue>
            <fpage>1031</fpage>
            <page-range>1031-7</page-range>
            <pub-id pub-id-type="pmid">10993010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khalid</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <chapter-title>Beta-Blocker Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">28846217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1828</fpage>
            <page-range>1828-35</page-range>
            <pub-id pub-id-type="pmid">16990629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janah</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galsgaard</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Winther-S&#x000f8;rensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stojanovska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Wewer Albrechtsen</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Glucagon Receptor Signaling and Glucagon Resistance.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>05</day>
            <volume>20</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">31284506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28847.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mubarik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerndt</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Sotalol</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>6</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30521253</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
